DAFNA Capital Management
Latest statistics and disclosures from DAFNA Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are XBI, CYTK, STXS, IDYA, SNDX, and represent 32.34% of DAFNA Capital Management's stock portfolio.
- Added to shares of these 10 stocks: SNDX (+$6.1M), BHVN (+$5.7M), SAGE (+$5.3M), IMGN, GLPG, SLRN, SPRY, DAWN, ARGX, ATXS.
- Started 7 new stock positions in MLYS, SAGE, ORIC, VTGN, ARGX, IMTX, SPRY.
- Reduced shares in these 10 stocks: BPMC (-$13M), XBI (-$7.2M), CYTK (-$6.6M), AUTL, NRIX, THRD, ASND, KRTX, CERE, VKTX.
- Sold out of its positions in ACET, CERE, MRSN, NXTC, NRIX, THRD.
- DAFNA Capital Management was a net seller of stock by $-15M.
- DAFNA Capital Management has $417M in assets under management (AUM), dropping by 29.82%.
- Central Index Key (CIK): 0001389933
Tip: Access up to 7 years of quarterly data
Positions held by DAFNA Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelPortfolio Holdings for DAFNA Capital Management
DAFNA Capital Management holds 76 positions in its portfolio as reported in the December 2023 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Spdr S&p Biotech Etf Etf (XBI) | 10.4 | $43M | -14% | 484k | 89.29 |
|
Cytokinetics Com New (CYTK) | 8.0 | $33M | -16% | 400k | 83.49 |
|
Stereotaxis Com New (STXS) | 5.7 | $24M | 14M | 1.75 |
|
|
Ideaya Biosciences (IDYA) | 4.4 | $18M | +3% | 516k | 35.58 |
|
Syndax Pharmaceuticals (SNDX) | 3.8 | $16M | +62% | 743k | 21.61 |
|
Ascendis Pharma A/s Sponsored Adr (ASND) | 3.7 | $16M | -9% | 124k | 125.95 |
|
Karuna Therapeutics Ord (KRTX) | 3.7 | $15M | -8% | 48k | 316.51 |
|
Revolution Medicines (RVMD) | 3.5 | $15M | +8% | 512k | 28.68 |
|
Ishares Nasdaq Biotech Indx Etf (IBB) | 3.3 | $14M | 103k | 135.85 |
|
|
Xenon Pharmaceuticals (XENE) | 3.1 | $13M | 277k | 46.06 |
|
|
Merus N V (MRUS) | 3.0 | $13M | -6% | 455k | 27.50 |
|
Blueprint Medicines (BPMC) | 2.5 | $10M | -55% | 111k | 92.24 |
|
Day One Biopharmaceuticals I (DAWN) | 2.4 | $10M | +17% | 687k | 14.60 |
|
Neurocrine Biosciences (NBIX) | 2.3 | $9.6M | 73k | 131.76 |
|
|
Dex (DXCM) | 2.0 | $8.4M | 68k | 124.09 |
|
|
Kalvista Pharmaceuticals (KALV) | 1.8 | $7.4M | 601k | 12.25 |
|
|
Biohaven (BHVN) | 1.7 | $7.2M | +382% | 169k | 42.80 |
|
Kura Oncology (KURA) | 1.7 | $7.1M | -10% | 493k | 14.38 |
|
Morphic Hldg (MORF) | 1.6 | $6.7M | 232k | 28.88 |
|
|
Tandem Diabetes Care Com New (TNDM) | 1.6 | $6.5M | 221k | 29.58 |
|
|
Axogen (AXGN) | 1.5 | $6.4M | 936k | 6.83 |
|
|
2seventy Bio Common Stock (TSVT) | 1.5 | $6.2M | 1.4M | 4.27 |
|
|
ImmunoGen (IMGN) | 1.4 | $5.7M | +133% | 194k | 29.65 |
|
Sage Therapeutics (SAGE) | 1.3 | $5.3M | NEW | 245k | 21.67 |
|
Galapagos Nv Spon Adr (GLPG) | 1.3 | $5.3M | +116% | 130k | 40.65 |
|
Mirati Therapeutics (MRTX) | 1.3 | $5.3M | -3% | 89k | 58.75 |
|
Edgewise Therapeutics (EWTX) | 1.2 | $4.9M | -13% | 449k | 10.94 |
|
Alector (ALEC) | 1.2 | $4.9M | -3% | 610k | 7.98 |
|
Viking Therapeutics (VKTX) | 1.1 | $4.6M | -22% | 248k | 18.61 |
|
AtriCure (ATRC) | 1.1 | $4.5M | 126k | 35.69 |
|
|
Arcus Biosciences Incorporated (RCUS) | 1.1 | $4.4M | +4% | 233k | 19.10 |
|
Century Therapeutics (IPSC) | 1.0 | $4.3M | 1.3M | 3.32 |
|
|
BioCryst Pharmaceuticals (BCRX) | 1.0 | $4.2M | +8% | 710k | 5.99 |
|
Ascendis Pharma A/s Note 2.250% 4/0 (Principal) | 1.0 | $4.1M | 4.0M | 1.03 |
|
|
Accuray Incorporated (ARAY) | 0.8 | $3.5M | 1.2M | 2.83 |
|
|
Astria Therapeutics (ATXS) | 0.8 | $3.4M | +51% | 449k | 7.68 |
|
Keros Therapeutics (KROS) | 0.7 | $3.0M | +12% | 74k | 39.76 |
|
Acelyrin (SLRN) | 0.7 | $2.8M | +4984% | 371k | 7.46 |
|
Procept Biorobotics Corp (PRCT) | 0.6 | $2.7M | -5% | 63k | 41.91 |
|
Mediwound Shs New (MDWD) | 0.6 | $2.6M | 258k | 10.17 |
|
|
Bicycle Therapeutics Sponsored Ads (BCYC) | 0.5 | $2.2M | 122k | 18.08 |
|
|
Brainsway Sponsored Ads (BWAY) | 0.5 | $2.0M | -28% | 309k | 6.48 |
|
Proqr Therapeutics N V Shs Euro (PRQR) | 0.4 | $1.9M | 941k | 1.98 |
|
|
Amylyx Pharmaceuticals (AMLX) | 0.4 | $1.8M | 123k | 14.72 |
|
|
Mereo Biopharma Group Spon Ads (MREO) | 0.4 | $1.8M | -19% | 779k | 2.31 |
|
Immunovant (IMVT) | 0.4 | $1.7M | +81% | 41k | 42.13 |
|
Silverback Therapeutics (SPRY) | 0.4 | $1.7M | NEW | 311k | 5.48 |
|
Compass Pathways Sponsored Ads (CMPS) | 0.4 | $1.7M | 193k | 8.75 |
|
|
Syros Pharmaceuticals Com New (SYRS) | 0.4 | $1.7M | -19% | 215k | 7.79 |
|
Spruce Biosciences (SPRB) | 0.4 | $1.6M | -3% | 549k | 2.93 |
|
Larimar Therapeutics (LRMR) | 0.4 | $1.5M | 324k | 4.55 |
|
|
Macrogenics (MGNX) | 0.4 | $1.5M | -41% | 152k | 9.62 |
|
Regulus Therapeutics (RGLS) | 0.3 | $1.4M | 1.1M | 1.28 |
|
|
Argen Se Sponsored Adr (ARGX) | 0.3 | $1.4M | NEW | 3.6k | 380.43 |
|
Gossamer Bio (GOSS) | 0.3 | $1.3M | 1.5M | 0.91 |
|
|
Cullinan Oncology (CGEM) | 0.3 | $1.3M | 127k | 10.19 |
|
|
Autolus Therapeutics Spon Ads (AUTL) | 0.3 | $1.2M | -79% | 191k | 6.44 |
|
Sutro Biopharma (STRO) | 0.3 | $1.2M | 283k | 4.29 |
|
|
Immatics Nv SHS (IMTX) | 0.3 | $1.1M | NEW | 105k | 10.53 |
|
Iteos Therapeutics (ITOS) | 0.3 | $1.1M | 99k | 10.95 |
|
|
Neuronetics (STIM) | 0.2 | $910k | 314k | 2.90 |
|
|
Oric Pharmaceuticals (ORIC) | 0.2 | $670k | NEW | 73k | 9.20 |
|
Acrivon Therapeutics Common Stock (ACRV) | 0.2 | $646k | +70% | 131k | 4.92 |
|
Nevro (NVRO) | 0.1 | $603k | 28k | 21.52 |
|
|
Compugen Ord (CGEN) | 0.1 | $406k | 205k | 1.98 |
|
|
Masimo Corporation (MASI) | 0.1 | $352k | 3.0k | 117.21 |
|
|
Adaptimmune Therapeutics Sponds Adr (ADAP) | 0.1 | $278k | 351k | 0.79 |
|
|
Vigil Neuroscience (VIGL) | 0.1 | $243k | -58% | 72k | 3.38 |
|
Elevation Oncology (ELEV) | 0.1 | $242k | 450k | 0.54 |
|
|
Vistagen Therapeutics Ord (VTGN) | 0.1 | $215k | NEW | 42k | 5.14 |
|
Spero Therapeutics (SPRO) | 0.0 | $184k | 125k | 1.47 |
|
|
Compass Therapeutics (CMPX) | 0.0 | $182k | 117k | 1.56 |
|
|
Karyopharm Therapeutics (KPTI) | 0.0 | $167k | 193k | 0.86 |
|
|
Mineralys Therapeutics (MLYS) | 0.0 | $131k | NEW | 15k | 8.60 |
|
Kinnate Biopharma (KNTE) | 0.0 | $119k | -52% | 50k | 2.37 |
|
Inogen (INGN) | 0.0 | $82k | 15k | 5.49 |
|
Past Filings by DAFNA Capital Management
SEC 13F filings are viewable for DAFNA Capital Management going back to 2010
- DAFNA Capital Management 2023 Q4 filed Feb. 14, 2024
- DAFNA Capital Management 2023 Q3 filed Nov. 14, 2023
- DAFNA Capital Management 2023 Q2 filed Aug. 14, 2023
- DAFNA Capital Management 2023 Q1 filed May 15, 2023
- DAFNA Capital Management 2022 Q4 filed Feb. 14, 2023
- DAFNA Capital Management 2022 Q3 filed Nov. 14, 2022
- DAFNA Capital Management 2022 Q2 filed Aug. 15, 2022
- DAFNA Capital Management 2022 Q1 filed May 16, 2022
- DAFNA Capital Management 2021 Q4 filed Feb. 14, 2022
- DAFNA Capital Management 2021 Q3 filed Nov. 15, 2021
- DAFNA Capital Management 2021 Q2 filed Aug. 16, 2021
- DAFNA Capital Management 2021 Q1 filed May 17, 2021
- DAFNA Capital Management 2020 Q4 filed Feb. 16, 2021
- DAFNA Capital Management 2020 Q3 filed Nov. 16, 2020
- DAFNA Capital Management 2020 Q2 filed Aug. 14, 2020
- DAFNA Capital Management 2020 Q1 filed May 15, 2020